PF-06372865 In Subjects With Chronic Low Back Pain

Pfizer

Status and phase: Completed; Phase 2

Conditions: Chronic Low Back Pain

Treatments: Drug: PF-06372865; Drug: Placebo; Drug: Naproxen

Study type: Interventional

Funder types: Industry

Identifiers

NCT02262754

B7431006

Details and patient eligibility

About

PF-06372865 In Subjects With Chronic Low Back Pain

Enrollment: 302 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

302 participants in 3 patient groups, including a placebo group

PF-06372865

Experimental group

Description:

Daily BID dosing for 4 weeks

Treatment:

Drug: PF-06372865

Placebo

Placebo Comparator group

Description:

Daily BID dosing for 4 weeks

Treatment:

Drug: Placebo

Naproxen

Active Comparator group

Description:

Daily BID dosing for 4 weeks

Treatment:

Drug: Naproxen